Molecure IDMC backs Phase II KITE trial continuation of OATD-01 in pulmonary sarcoidosis

• Molecure received an independent monitoring panel recommendation to continue its Phase II KITE trial of OATD-01 in active pulmonary sarcoidosis unchanged.
• Results have not been presented; the decision followed an interim review of safety and efficacy data from the first 30 treated patients.
• A futility assessment indicated the study still has a credible path to meeting its primary endpoint, supporting continued investment in the program.
• Blinded biomarker readouts showed inflammation trends consistent with the drug’s expected effect, pending unblinding for confirmation.
• The trial is enrolling 20 more patients for a final interim analysis that will reassess the required sample size, a potential driver of cost and timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecure SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608041004OMX_____CNEWS_DE_GNW1001256019_de) on August 04, 2026, and is solely responsible for the information contained therein.